Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.69) by 28.06 percent. This is a 19.35 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $281.266 million which beat the analyst consensus estimate of $271.011 million by 3.78 percent. This is a 39.37 percent increase over sales of $201.814 million the same period last year.